Objective: To evaluate the intrauterine management and perinatal outcome of pregnancies complicated by giant placental chorioangioma (>4 cm) and elaborate on various devascularization techniques. Materials and Methods: Retrospective review of 10 cases of giant placental chorioangioma evaluated between January 2005 and August 2012. Maternal demographics, prenatal imaging, response to fetoscopic treatment, obstetrical complications, and perinatal outcomes were evaluated. Results: Overall survival was 80%. Seven (70%) cases were associated with obstetrical complications, including polyhydramnios (n = 7), non-immune hydrops (n = 3), and high cardiac output state (n = 5). Five patients underwent fetoscopic devascularization at a mean gestational age of 24.03 weeks with 80% survival. The tumors were devascularized by bipolar coagulation (n = 1), combination of bipolar and diode laser (n = 2), bipolar and radiofrequency ablation (n = 1), and surgical clip application (n = 1). Postoperatively, all survivors had resolution of hydrops and high cardiac output states with survival beyond 60 days of life. Discussion: Fetoscopic devascularization is indicated for high cardiac output states or non-immune hydrops and may require multiple techniques including bipolar coagulation, clip application, and/or laser to interrupt arterial inflow and devascularize the mass.

Keywords:
Giant chorioangioma, Placenta, Fetoscopy, Fetoscopic devascularization, High cardiac output, Hydrops fetalis
1.
Fox H, Sebire NJ (eds): Non-trophoblastic tumors of the placenta; in Pathology of the Placenta. Philadelphia, Saunders Elsevier, 2007, pp 401-430.
2.
Fox H, Elston CW: Pathology of the Placenta. Major Problems in Pathology. Philadelphia, Saunders, 1978, p xvii, 491.
3.
Quintero RA, Reich H, Romero R, Johnson MP, Goncalves L, Evans MI: In utero endoscopic devascularization of a large chorioangioma. Ultrasound Obstet Gynecol 1996;8:48-52.
4.
Sepulveda W, Alcalde JL, Schnapp C, Bravo M: Perinatal outcome after prenatal diagnosis of placental chorioangioma. Obstet Gynecol 2003;102:1028-1033.
5.
Zanardini C, Papageorghiou A, Bhide A, Thilaganathan B: Giant placental chorioangioma: natural history and pregnancy outcome. Ultrasound Obstet Gynecol 2010;35:332-336.
6.
Hamill N, Rijhsinghani A, Williamson RA, Grant S: Prenatal diagnosis and management of fetal anemia secondary to a large chorioangioma. Obstet Gynecol 2003;102:1185-1188.
7.
Hirata GI, Masaki DI, O'Toole M, Medearis AL, Platt LD: Color flow mapping and Doppler velocimetry in the diagnosis and management of a placental chorioangioma associated with non-immune fetal hydrops. Obstet Gynecol 1993;81:850-852.
8.
Bermudez C, Luengas O, Perez-Wulff J, Genatios U, Garcia V, Guevara-Zuloaga F, Quintero RA: Management of a placental chorioangioma with endoscopic devascularization and intrauterine transfusions. Ultrasound Obstet Gynecol 2007;29:97-98.
9.
Wanapirak C, Tongsong T, Sirichotiyakul S, Chanprapaph P: Alcoholization: the choice of intrauterine treatment for chorioangioma. J Obstet Gynaecol Res 2002;28:71-75.
10.
Mendez-Figueroa H, Papanna R, Popek EJ, Byrd RH, Goldaber K, Moise KJ Jr, Johnson A: Endoscopic laser coagulation following amnioreduction for the management of a large placental chorioangioma. Prenat Diagn 2009;29:1277-1278.
11.
Jones K, Tierney K, Grubbs BH, Pruetz JD, Detterich J, Chmait RH: Fetoscopic laser photocoagulation of feeding vessels to a large placental chorioangioma following fetal deterioration after amnioreduction. Fetal Diagn Ther 2012;31:191-195.
12.
Garcia-Diaz L, Carreto P, Costa-Pereira S, Antinolo G: Prenatal management and perinatal outcome in giant placental chorioangioma complicated with hydrops fetalis, fetal anemia and maternal mirror syndrome. BMC Pregnancy Childbirth 2012;12:72.
13.
Deren O, Ozyuncu O, Onderoglu LS, Durukan T: Alcohol injection for the intrauterine treatment of chorioangioma in a pregnancy with transfusion-resistant fetal anemia: a case report. Fetal Diagn Ther 2007;22:203-205.
14.
Nicolini U, Zuliani G, Caravelli E, Fogliani R, Poblete A, Roberts A: Alcohol injection: a new method of treating placental chorioangiomas. Lancet 1999;353:1674-1675.
15.
Ercan CM, Coksuer H, Karasahin KE, Alanbay I, Baser I: Combined approach in a large placental chorioangioma case with intratumoral alcohol injection, cordocentesis, IU transfusion, and amnioreduction. Fetal Pediatr Pathol 2012;31:374-378.
16.
Lau TK, Leung TY, Yu SC, To KF, Leung TN: Prenatal treatment of chorioangioma by microcoil embolisation. BJOG 2003;110:70-73.
17.
Lau TK, Yu SC, Leung TY, To KF, Fung TY, Leung TN: Prenatal embolisation of a large chorioangioma using enbucrilate. BJOG 2005;112:1002-1004.
18.
Bhide A, Prefumo F, Sairam S, Carvalho J, Thilaganathan B: Ultrasound-guided interstitial laser therapy for the treatment of placental chorioangioma. Obstet Gynecol 2003;102:1189-1191.
19.
Quarello E, Bernard JP, Leroy B, Ville Y: Prenatal laser treatment of a placental chorioangioma. Ultrasound Obstet Gynecol 2005;25:299-301.
20.
Sepulveda W, Wong AE, Herrera L, Dezerega V, Devoto JC: Endoscopic laser coagulation of feeding vessels in large placental chorioangiomas: report of three cases and review of invasive treatment options. Prenat Diagn 2009;29:201-206.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.